NNVC (NanoViricides Inc.) Projected Price to Earnings

Official company branding of NanoViricides Inc. (NNVC)

The forward P/E ratio of NanoViricides, Inc. (NNVC) correlates with geopolitical risks and government demand for protection against bio-threats. Meanwhile, the 0.00 indicator determines the magnitude of this metric amid a revenue deficit and the depletion of cash reserves. Business stability relies on innovative "nanosponges" for virus elimination, confirming the high scientific potential of NanoViricides, Inc. (NNVC) within the biotechnology sector.

NNVC - nanoviricides.com Market Cap to Projected Earnings over the range 07/04/2022 - 11/13/2026

Analytical breakdowns for NanoViricides, Inc.

- current price and projected stock value:
Stock Quotes NanoViricides, Inc.|NNVC - Fair Value Consensus
- business market valuation indicators:
Market Valuation NanoViricides Inc.|NNVC - Total Company Value
- issuer book value statistics:
Book Value per Share NanoViricides|NNVC - Book Valuation of Business|Market Value to Book Value Ratio nanoviricides.com|NNVC - Aggregate Asset Value
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio NanoViricides, Inc.|NNVC - Long-Term Debt to Capital|Short-Term Debt to Equity NanoViricides, Inc.|NNVC - Company Total Debt Obligations|Debt to Book Capitalization Ratio NanoViricides Inc.|NNVC - Company Long-Term Indebtedness|Company Short-Term Debts NanoViricides|Quick Liquidity nanoviricides.com
- earnings and market ratios statistics:
NNVC - Company Profit|Expected Profit NanoViricides, Inc.|NNVC - Market Cap to Earnings|Projected Price to Earnings NanoViricides, Inc.|NNVC - Price/Earnings to Growth Ratio|EV/EBITDA Multiple NanoViricides Inc.|NNVC - Operating income before deduction of amortization|Earnings per share for the last twelve months NanoViricides|NNVC - Earnings per share for the trailing year|Quarterly EPS earnings growth nanoviricides.com|NNVC - Expected net earnings per share growth this year|Earnings growth forecast for next year NanoViricides, Inc.
Basic company analysis:NNVC NanoViricides
Product sample of NanoViricides, Inc.

Forward P/E measures an asset's market value relative to expected earnings, reflecting cash flow discount rates and the level of investor optimism. Analyzing the forward P/E valuation of NanoViricides, Inc. (NNVC) reveals how the company's low capital expenditures, achieved through outsourcing clinical trials, impact projected profitability and the fundamental attractiveness of this business model.

Who NanoViricides, Inc. competes with

Projected Price to Earnings GILD (Gilead Sciences)|CDTX (Cidara Therapeutics) - Future Price to Earnings Multiple|Novavax Corp - Projected Price to Earnings|CureVac Pharma - Future Price to Earnings|Valneva SE - Forward P/E Multiple|Market Cap to Projected Earnings vir.bio VIR|SIGA Technologies (SIGA) - Future Price to Earnings|Emergent BioSolutions Inc - Future Price to Earnings Multiple|Projected Price to Earnings AVIR|Forward P/E Multiple Invivyd Corp|Future Price to Earnings Enanta Pharmaceuticals (ENTA)|Market Cap to Projected Earnings inovio.com|Future Price to Earnings HilleVax HLVX|KLRS: Price to Future Earnings Ratio|Dyadic - Forward P/E Multiple|TLPH - Forward P/E Multiple|Cocrystal Pharma, Inc. (COCP) - Future Price to Earnings|Price to Future Earnings Ratio TRAW|Future Price to Earnings Dogwood Therapeutics Inc.|Projected Price to Earnings Ratio Qualigen Therapeutics Inc QLGN|Projected Price to Earnings ALVR (AlloVir, Inc.)|Future Price to Earnings VBIV (vbivaccines.com)|Forward P/E Multiple VIRI (Virios Therapeutics, Inc.)|Market Cap to Projected Earnings Vaxart Inc. (VXRT)